Gilead Sciences, Inc. (GILD) Shares Bought by Oppenheimer Asset Management Inc.

Oppenheimer Asset Management Inc. grew its holdings in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 124.0% in the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 20,054 shares of the biopharmaceutical company’s stock after acquiring an additional 11,100 shares during the quarter. Oppenheimer Asset Management Inc.’s holdings in Gilead Sciences were worth $1,548,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also modified their holdings of the business. James Investment Research Inc. grew its holdings in shares of Gilead Sciences by 152.5% during the third quarter. James Investment Research Inc. now owns 49,935 shares of the biopharmaceutical company’s stock worth $3,856,000 after purchasing an additional 30,157 shares during the last quarter. Hallmark Capital Management Inc. grew its holdings in shares of Gilead Sciences by 8.1% during the third quarter. Hallmark Capital Management Inc. now owns 29,440 shares of the biopharmaceutical company’s stock worth $2,273,000 after purchasing an additional 2,205 shares during the last quarter. Trust Co. of Vermont grew its holdings in shares of Gilead Sciences by 2.7% during the third quarter. Trust Co. of Vermont now owns 44,229 shares of the biopharmaceutical company’s stock worth $3,415,000 after purchasing an additional 1,161 shares during the last quarter. Russell Investments Group Ltd. grew its holdings in shares of Gilead Sciences by 5.1% during the third quarter. Russell Investments Group Ltd. now owns 1,974,770 shares of the biopharmaceutical company’s stock worth $151,971,000 after purchasing an additional 95,171 shares during the last quarter. Finally, Dorsey & Whitney Trust CO LLC grew its holdings in shares of Gilead Sciences by 10.7% during the third quarter. Dorsey & Whitney Trust CO LLC now owns 8,480 shares of the biopharmaceutical company’s stock worth $655,000 after purchasing an additional 822 shares during the last quarter. 78.23% of the stock is owned by hedge funds and other institutional investors.

In related news, Director John C. Martin sold 50,000 shares of the company’s stock in a transaction that occurred on Tuesday, September 4th. The stock was sold at an average price of $74.16, for a total value of $3,708,000.00. Following the sale, the director now directly owns 3,067,762 shares in the company, valued at $227,505,229.92. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Corporate insiders own 1.30% of the company’s stock.

Several research firms have recently weighed in on GILD. Morgan Stanley boosted their price target on Gilead Sciences from $81.00 to $85.00 and gave the stock an “equal weight” rating in a report on Thursday, July 26th. Piper Jaffray Companies set a $85.00 price target on Gilead Sciences and gave the stock a “buy” rating in a report on Wednesday, September 12th. Mizuho set a $94.00 price target on Gilead Sciences and gave the stock a “buy” rating in a report on Thursday. Zacks Investment Research cut Gilead Sciences from a “strong-buy” rating to a “hold” rating in a report on Tuesday, September 25th. Finally, BidaskClub upgraded Gilead Sciences from a “sell” rating to a “hold” rating in a report on Tuesday, July 10th. Thirteen equities research analysts have rated the stock with a hold rating, ten have given a buy rating and one has given a strong buy rating to the company. Gilead Sciences has a consensus rating of “Buy” and a consensus target price of $87.84.

Shares of GILD stock opened at $69.44 on Friday. Gilead Sciences, Inc. has a one year low of $64.27 and a one year high of $89.54. The company has a market capitalization of $90.02 billion, a P/E ratio of 10.82, a P/E/G ratio of -2.69 and a beta of 1.01. The company has a current ratio of 3.47, a quick ratio of 3.39 and a debt-to-equity ratio of 1.36.

Gilead Sciences (NASDAQ:GILD) last announced its earnings results on Thursday, October 25th. The biopharmaceutical company reported $1.84 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $1.63 by $0.21. Gilead Sciences had a return on equity of 39.32% and a net margin of 7.12%. The business had revenue of $5.60 billion for the quarter, compared to analysts’ expectations of $5.44 billion. During the same period in the prior year, the business posted $2.27 earnings per share. As a group, sell-side analysts anticipate that Gilead Sciences, Inc. will post 6.44 EPS for the current fiscal year.

The business also recently announced a quarterly dividend, which will be paid on Friday, December 28th. Investors of record on Friday, December 14th will be issued a $0.57 dividend. This represents a $2.28 annualized dividend and a yield of 3.28%. The ex-dividend date of this dividend is Thursday, December 13th. Gilead Sciences’s payout ratio is presently 26.64%.

About Gilead Sciences

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes therapeutics in the areas of unmet medical needs in the United States, Europe, and internationally. The company's products include Biktarvy, Descovy, Odefsey, Genvoya, Stribild, Complera/Eviplera, Atripla, Truvada, Viread, Emtriva, and Tybost for the treatment of human immunodeficiency virus (HIV) infection in adults; and Vosevi, Vemlidy, Epclusa, Harvoni, Sovaldi, Viread, and Hepsera products for treating liver diseases.

See Also: Asset Allocation, Balancing Your Investments

Want to see what other hedge funds are holding GILD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Gilead Sciences, Inc. (NASDAQ:GILD).

Institutional Ownership by Quarter for Gilead Sciences (NASDAQ:GILD)

Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply